Match!
Ramesh K. Ramanathan
Translational Genomics Research Institute
PharmacokineticsCancerPathologyMedicinePharmacology
268Publications
43H-index
12kCitations
What is this?
Publications 348
Newest
#1David GoldsteinH-Index: 84
#2Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
Last. Brian LuH-Index: 7
view all 13 authors...
OBJECTIVES This analysis investigated nomogram use to evaluate metastatic pancreatic cancer prognosis. METHODS Thirty-four baseline factors were examined in the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) (nab-paclitaxel plus gemcitabine vs gemcitabine) data set. Factors significantly (P < 0.1) associated with overall survival (OS) in a univariable model or with known clinical relevance were tested further. In a multivariable model, factors associated with OS (P < 0.1) were selec...
Source
#1Devalingam Mahalingam (NU: Northwestern University)H-Index: 26
#2Manish R. Patel (Sarah Cannon Research Institute)H-Index: 23
Last. Floris A. de Jong (Takeda Pharmaceutical Company)H-Index: 1
view all 11 authors...
AIM: Preclinical evidence suggests that oxidized macrophage migration inhibitory factor (oxMIF) may be involved in carcinogenesis. This phase 1 study (NCT01765790) assessed safety, tolerability, pharmacokinetics and antitumor activity of imalumab, an oxidized macrophage migration inhibitory factor (oxMIF) inhibitor, in patients with advanced cancer using '3+3' dose-escalation. METHODS: In Schedule 1, patients with solid tumors received doses from 1-50 mg/kg IV every two weeks. In Schedule 2, pat...
1 CitationsSource
#1Ramesh K. Ramanathan (TGen: Translational Genomics Research Institute)H-Index: 43
#2Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
Last. C. Pena (Bayer AG: Bayer HealthCare Pharmaceuticals)H-Index: 9
view all 11 authors...
BACKGROUND: Dual inhibition of PI3K and MAPK signaling is conceptually a promising anticancer therapy. OBJECTIVE: This phase 1b trial investigated the safety, maximum tolerated dose (MTD), recommended phase II dose, pharmacokinetics, tumor response, fluorodeoxyglucose positron emission tomography (FDG-PET) pharmacodynamics, and biomarker explorations for the combination of pan-PI3K inhibitor copanlisib and allosteric MEK inhibitor refametinib in patients with advanced solid tumors. PATIENTS AND ...
Source
#1John H. Strickler (Duke University)H-Index: 12
#2Patricia LoRusso (Yale Cancer Center)H-Index: 60
Last. Huibin Yue (Genentech)
view all 15 authors...
This first-in-human phase 1 study evaluated the pharmacokinetics, safety, and preliminary efficacy of telisotuzumab, formerly called ABT-700, an antagonistic antibody directed against c-Met. For dose-escalation (3+3 design), three to six patients with advanced solid tumors were enrolled into four dose cohorts (5-25 mg/kg). In the dose-expansion phase, a subset of patients were prospectively selected for MET amplification (FISH screening). Patients received telisotuzumab intravenously on day 1 ev...
1 CitationsSource
#1Ana De Jesus-Acosta (Johns Hopkins University)H-Index: 13
#2Elizabeth A. Sugar (Johns Hopkins University)H-Index: 32
Last. Daniel Laheru (Johns Hopkins University)H-Index: 46
view all 17 authors...
The Hedgehog (Hh) signalling pathway is overexpressed in pancreatic ductal adenocarcinoma (PDA). Preclinical studies have shown that Hh inhibitors reduce pancreatic cancer stem cells (pCSC), stroma and Hh signalling. Patients with previously untreated metastatic PDA were treated with gemcitabine and nab-paclitaxel. Vismodegib was added starting on the second cycle. The primary endpoint was progression-free survival (PFS) as compared with historical controls. Tumour biopsies to assess pCSC, strom...
2 CitationsSource
#1Madappa N. Kundranda (University of Texas MD Anderson Cancer Center)H-Index: 5
#2David Propper (St Bartholomew's Hospital)H-Index: 23
Last. Leonardo O. RodriguesH-Index: 2
view all 16 authors...
723Background: BPM31510-IV is an Ubidecarenone (CoQ10) drug-lipid conjugate nanodispersion targeting metabolic machinery in cancer, shifting bioenergetics from lactate dependency towards mitochondr...
Source
#1Gayle S. Jameson (TGen: Translational Genomics Research Institute)H-Index: 12
#2Erkut Borazanci (TGen: Translational Genomics Research Institute)H-Index: 8
Last. Daniel D. Von Hoff (TGen: Translational Genomics Research Institute)H-Index: 84
view all 16 authors...
Importance Genomes of metastatic pancreatic cancers frequently contain intrachromosomal aberrations, indicating a DNA repair deficiency associated with sensitivity to DNA damaging agents, such as platinum. Objective To determine response rate following treatment with nab-paclitaxel plus gemcitabine plus platinum-based cisplatin for patients with metastatic pancreatic ductal adenocarcinoma (PDA). Design, Setting, and Participants This was a single-arm, open-label, phase 1b/2 clinical trial of nab...
1 CitationsSource
#1Vera GorbunovaH-Index: 52
#2J. Thaddeus BeckH-Index: 1
Last. Jordan Berlin (Vandy: Vanderbilt University)H-Index: 51
view all 14 authors...
The original version of this article contained an error in Figure 1a. The number of patients at risk listed in the Veliparib arm of Figure 1a should have read “65” instead of “35”. An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Source
#1Rachna T. Shroff (UA: University of Arizona)H-Index: 17
#2Milind Javle (University of Texas MD Anderson Cancer Center)H-Index: 28
Last. Mitesh J. Borad (Mayo Clinic)H-Index: 35
view all 13 authors...
Importance Administration of gemcitabine-cisplatin, the current standard therapy for advanced biliary tract cancers, results in median progression-free survival and overall survival of 8.0 and 11.7 months, respectively. New treatments offering improved survival outcomes are therefore needed. Objective To evaluate the association between progression-free survival and the addition of nanoparticle albumin-bound (nab)–paclitaxel to gemcitabine-cisplatin for the treatment of patients with advanced bi...
8 CitationsSource
#1Ramesh K. Ramanathan (Mayo Clinic)H-Index: 13
#2Shannon McDonough (Fred Hutchinson Cancer Research Center)H-Index: 10
Last. Howard S. Hochster (RU: Rutgers University)H-Index: 18
view all 15 authors...
PURPOSEPegylated recombinant human hyaluronidase (PEGPH20) degrades hyaluronan (HA) and, in combination with chemotherapy, prolongs survival in preclinical models. The activity of PEGPH20 with modified fluorouracil, leucovorin, irinotecan, and oxaliplatin (mFOLFIRINOX) was evaluated in patients with metastatic pancreatic cancer (mPC).MATERIALS AND METHODSPatients had untreated mPC, a performance status of 0 to 1, and adequate organ function. Tumor HA status was not required for eligibility. Afte...
4 CitationsSource
12345678910